Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes. Nagano Y, Yokouchi H, Saito R, Honjo O, et al. Cancer Sci 2026 May 31. doi: 10.1111/cas.70400.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nagano Y, Yokouchi H, Saito R, Honjo O, et al. Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes. Cancer Sci 2026 May 31. doi: 10.1111/cas.70400.
PMID: 42218657